This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview

This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

The New Paradigm in Atopic Dermatitis Treatment

The New Paradigm in Atopic Dermatitis Treatment

Format

Webcast

Time to Complete

1.75 hours

Released

March 31, 2019

Expires

March 30, 2020
Add to Queue


Maximum Credits

1.75 / AMA PRA Category 1 CreditsTM
1.75 AANP Contact Hours

Accredited Provider

Provided by the Annenberg Center for Health Sciences at Eisenhower

Commercial Supporter

This educational activity is supported by an independent educational grant from Pfizer, Inc.

Program Description

Steven Feldman, MD, PhD, and Jonathan Silverberg, MD, PhD, MPH, provide their clinical insights into the burden of disease experienced by persons with atopic dermatitis and strategies for management. They discuss how improved understanding of pathophysiologic mechanisms has led to the availability of new topical and systemic therapies that, when integrated with other therapies, can reduce patients’ disease burden. They also discuss 6 medications in late-stage development for atopic dermatitis.

Intended Audience

This activity is intended for dermatologists, pediatric dermatologists, allergists, along with nurse practitioners and physician assistants within those specialties who manage patients with atopic dermatitis.

Educational Objectives

Upon completion of this activity, participants will be able to:

  • Recognize essential and important signs and symptoms that should be considered in the diagnosis of atopic dermatitis (AD)
  • Develop treatment plans that address both symptoms and patient concerns
  • Integrate newly-approved AD therapies into treatment plans
  • Describe emerging AD treatments in late-stage clinical development

Conflict Of Interest Disclosure Policy

It is the policy of the Annenberg Center for Health Sciences to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All faculty and planners participating in sponsored programs are expected to identify and reference off-label product use and disclose any relationship with those supporting the activity or any others with products or services available within the scope of the topic being discussed in the educational presentation.

The Annenberg Center for Health Sciences assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CE/CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CE/CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.

In accordance with the Accreditation Council for Continuing Medical Education Standards, parallel documents from other accrediting bodies, and Annenberg Center for Health Sciences policy, the following disclosures have been made:

Faculty

Steven R. Feldman, MD, PhD
Professor of Dermatology, Pathology and Public Health Sciences
Department of Dermatology
Wake Forest School of Medicine
Winston-Salem, North Carolina

Dr. Feldman discloses the following:
Research Support: AbbVie: Clinical area: Psoriasis; Celgene: Clinical area: Psoriasis;; Janssen: Clinical area: Psoriasis; Lilly: Clinical area: Psoriasis; Novartis: Clinical area: Psoriasis; Pfizer: Clinical area: Atopic Dermatitis; Taro: Clinical area: Psoriasis, Atopic Dermatitis
Consultant: AbbVie: Clinical area: Psoriasis; Alvotech: Clinical area: Psoriasis; Boehringer: Clinical area: Psoriasis; Bristol-Myers Squibb: Clinical area: Atopic Dermatitis; Celgene: Clinical area: Psoriasis; Janssen: Clinical area: Psoriasis; Leo: Clinical area: Psoriasis; Lilly: Clinical area: Psoriasis; Merck: Clinical area: Psoriasis; Novartis: Clinical area: Psoriasis; Ortho: Clinical area: Psoriasis; Regeneron: Clinical area: Atopic Dermatitis; Samsung: Clinical area: Psoriasis; Sanofi: Clinical area: Atopic Dermatitis; Sun: Clinical area: Psoriasis
Speakers Bureau: AbbVie: Clinical area: Psoriasis; Celgene: Clinical area: Psoriasis; Janssen: Clinical area: Psoriasis ; Leo: Clinical area: Psoriasis; Lilly: Clinical area: Psoriasis; Novartis: Clinical area: Psoriasis; Ortho: Clinical area: Psoriasis; Regeneron: Clinical area: Atopic Dermatitis; Sanofi: Clinical area: Atopic Dermatitis ; Sun: Clinical area: Psoriasis; Significant Shareholder: Causa Research, DrScore

Jonathan Silverberg, MD, PhD, MPH
Director, Northwestern Medicine Multidisciplinary Eczema Center, Director, Contact Dermatitis Clinic, Northwestern Memorial Hospital, Associate Professor, Departments of Dermatology, Preventive Medicine and Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois

Dr. Silverberg discloses the following:
Research Support: GlaxoSmithKline: Clinical area: Atopic Dermatitis
Consultant: AbbVie: Clinical area: Atopic Dermatitis; Asana: Clinical area: Atopic Dermatitis; Dermavant: Atopic Dermatitis; Galderma: Clinical area: Atopic Dermatitis; GlaxoSmithKline: Clinical area: Atopic Dermatitis; Glenmark: Clinical area: Atopic Dermatitis; Kiniksa: Clinical area: Atopic Dermatitis; Leo: Clinical area: Atopic Dermatitis; Lilly: Clinical area: Atopic Dermatitis; Menlo: Atopic Dermatitis; Pfizer: Atopic Dermatitis; Realm: Atopic Dermatitis ; Regeneron-Sanofi: Atopic Dermatitis
Speakers Bureau: Regeneron-Sanofi: Atopic Dermatitis

Accredited Provider Disclosure

Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

Publishing Staff Disclosures

The following have no significant relationship to disclose:

Additional content planners
Greg Scott, RPH, PharmD (medical writer)
Heather Jimenez, NP (nurse planner)
Keyan Matinpour, MD (peer reviewer)

Credit

1.75

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation Statement

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.75 AMA PRA Category 1 CreditsTM  .  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit

1.75

Type

CE for Nurse Practitioners

Accreditation Statement

Annenberg Center for Health Sciences at Eisenhower is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 040207.

Designation Statement

This program is accredited for 1.75 contact hours. Program ID #5694-EM

Disclosure of Unlabeled Use

The faculty for this activity has disclosed that there will be discussion about the use of products for non-FDA approved indications.

Disclaimer

The ideas and opinions presented in this educational activity are those of the faculty and do not necessarily reflect the views of the Annenberg Center and/or its agents. As in all educational activities, we encourage practitioners to use their own judgment in treating and addressing the needs of each individual patient, taking into account that patient’s unique clinical situation. The Annenberg Center disclaims all liability and cannot be held responsible for any problems that may arise from participating in this activity or following treatment recommendations presented.

Instructions

This activity is an online enduring material. Successful completion is achieved by reading and/or viewing the material, reflecting on its implications for your practice, and completing the assessment component.

Please note: The content of this activity is housed on the website of our educational partner, Annenberg Center for Health Sciences at Eisenhower, and requires you to leave myCME and register on the Annenberg website.

Your certificate will be saved on the Annenberg website only and cannot be accessed in your myCME CME History. Please go to https://education.annenberg.net and sign in to access your certificate in the future.

Contact Information

For help or questions about this Internet activity, please contact Annenberg Continuing Education:
ce@annenberg.net
Annenberg Center for Health Sciences
39000 Bob Hope Drive
Dinah Shore Building
Rancho Mirage, CA 92270
Phone: 760-773-4500
Fax: 760-773-4513
8 AM – 5 PM, Pacific Time, Monday – Friday

Privacy Policy

Annenberg Center for Health Sciences respects your privacy. We don’t share information you give us, or have the need to share this information in the normal course of providing the services and information you may request. If there should be a need or request to share this information, we will do so only with your explicit permission. See Privacy Statement and other information at http://www.annenberg.net/privacy-policy/

myCME privacy policy
Add to Queue